Biomedicine Daily · Monday, 12 October 2026
CBA FRONTIER INSIGHTS
Novartis Licenses Abogen mRNA T Cell Engager for $575 Million Upfront
Novartis has secured global rights to ABO2203, an mRNA-encoded CD19-targeted T cell engager from Abogen Biosciences, paying $575 million upfront with up to $7.2 billion in milestones attached, plus an option on follow-on RNA projects. The bet lands two weeks after a Ruijin Hospital team and Abogen published an exploratory study of the molecule in refractory immune thrombocytopenia in Cell. Elsewhere, the day brought a null result that matters: in a NEJM trial of 963 emergency department patients in septic shock, early vasopressors with restricted fluids matched higher fluid volumes and later vasopressors — median 76 days alive and out of hospital at day 90 in both groups — though pulmonary edema was rarer with the vasopressor strategy (0.6% vs 5.0%). Merck's remigromig also posted non-inferior vision outcomes versus anti-VEGF therapy in pivotal DME trials at one year.
Clinical readouts and safety
Vasopressors or Fluids in Early Septic Shock.
Early vasopressor therapy with restricted fluids did not improve outcomes over higher fluid volumes with later vasopressors in emergency department patients with septic shock. In 963 intention-to-treat patients, days alive and out of the hospital at day 90 were a median of 76 in both groups (difference, 0.0 days; 95% CI, -2.7 to 2.7; P = 1.00). Pulmonary edema was less frequent with the vasopressor strategy (0.6% vs. 5.0%; P<0.001).
Merck's Remigromig Matches Anti-VEGF Vision Outcomes in DME at One Year
Remigromig, a tetravalent trispecific agonist targeting the Wnt pathway, met the primary goal of non-inferiority to anti-VEGF therapy for vision outcomes in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema. Merck presented the one-year results at AAO 2026. Remigromig is the first biologic with a new mechanism of action to show vision non-inferiority versus anti-VEGF treatment in a pivotal DME trial, a setting where up to 40% of patients have persistent disease after six months.
Industry and deals
Novartis Pays $575 Million Upfront for Global Rights to Abogen mRNA T Cell Engager ABO2203
Novartis has licensed global rights to ABO2203, an mRNA-encoded CD19-targeted T cell engager, from Abogen Biosciences, with an option on follow-on RNA projects. The deal includes $575 million upfront and up to $7.2 billion in milestones, for a total of $7.775 billion. Two weeks before the announcement, a Ruijin Hospital team and Abogen published an exploratory clinical study of the molecule in refractory immune thrombocytopenia in Cell.
Envisagenics and Boehringer Ingelheim Strike Over $1 Billion RNA Splicing Collaboration for Solid Tumours
Envisagenics and Boehringer Ingelheim entered a multi-year research collaboration and option agreement announced on September 22, 2026, worth more than $1 billion in total. The partners will validate selected tumour-specific targets and develop first-in-class precision therapies for solid tumours, using Envisagenics' AI-driven approach that turns alternative RNA splicing into a drug discovery frontier.
Research papers
Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors.
Armoring CAR T cells with a secreted tenascin-C-targeted single-chain variable fragment (TNC-scFv) enhanced cytotoxicity, persistence, and reduced exhaustion in vitro and in xenograft tumor models. Single-cell transcriptomics showed the approach reprograms the tumor microenvironment toward a CD8+ T cell-enriched, functionally active immune landscape, and humanized tumor models showed robust antitumor responses with minimal systemic toxicity. Combining the armoring with interleukin-2 further increased efficacy while mitigating cytokine-associated toxicity, establishing extracellular matrix-directed armoring as a generalizable strategy for solid tumors.
FAPI-46 PET/CT Beats FDG PET/CT in Characterizing Indeterminate Liver Lesions
Gallium-FAPI-46 PET/CT reached 100% sensitivity in characterizing indeterminate liver lesions, outperforming FDG PET/CT at 70% in a prospective head-to-head study by Medical University of Graz researchers. Dynamic imaging separated benign from malignant lesions: benign lesions showed transient high uptake that cleared within 10 minutes, while malignant lesions showed persistent high uptake. FAPI-46 also showed longer tumor retention and higher image contrast than FAPI-04.
doi.orgTopological Engineering of NIR-II Emissive Conjugated Oligomers With Unexpected Excited-State Manifolds for Efficient Phototheranostics and Cancer Immunotherapy
Topology-driven excited-state engineering of conjugated oligomers yields nanoparticles that improve both imaging and therapy. Under 808 nm laser irradiation, TBT-3 nanoparticles showed 2.8-fold enhanced NIR-II fluorescence brightness, 2.7-fold improved photothermal performance, and 7.5-fold increased total ROS generation versus TBT-1. In vivo, TBT-3 nanoparticles enabled high-resolution NIR-II fluorescence imaging and tumor elimination, and phototherapy induced immunogenic cell death, improving efficacy combined with anti-PD-1 blockade.
doi.orgBiomarker and Bioorthogonality Dual-Locked Chemiluminescent Probes for Cancer Urine Test
Chemiluminescent tetrazine probes (CLTZs) stay dark until a bioorthogonal reaction with bicyclononyne (BCN) unlocks emission, enabling biomarker and bioorthogonality dual-locked cancer urine testing. Pairing an H2O2 and BCN dual-locked probe (HBCP) with a cancer-activatable urinary reporter (CBUR) gave in vivo tumor imaging with a signal-to-background ratio of 438 and detected lung metastasis in urinary assays with up to 23.9-fold signal enhancement over healthy mice. The work adds a molecular design route to noninvasive chemiluminescent diagnostics.
Massively scaled variant effect mapping across the MAPK pathway reveals the importance of molecular and cellular context
Variant effect mapping of 186,676 variants across 17 RAS-MAPK pathway proteins in human cells, totaling 503,099 measurements of protein abundance and pathway activity, revealed 14,412 dominant negative variants across 12 proteins, nearly all previously unknown and depleted from the human population. HSP90 inhibition experiments showed HSP90 shapes the effect of 67% of missense variants across the pathway. The data also resolved how the KRAS switch II helix surface accommodates overlapping LZTR1 and SOS1 interactions through distinct allosteric networks.
Epigenetic Remodeling of Hippocampal CA2 Perineuronal Nets Underlies Sevoflurane Neurotoxicity in the Developing Brain
A team led by Zhang Hui, Zhang Haopeng, Liang Lirong and Wu Shengxi reports in Advanced Science that sevoflurane exposure during the developmental window injures the brain through epigenetic regulation that remodels perineuronal nets in hippocampal region CA2. The work ties repeated sevoflurane exposure in children, a risk previously linked to long-term learning and memory impairment, to a defined molecular mechanism acting on CA2 excitatory pyramidal neurons, the cells that carry social memory. It identifies a cellular and epigenetic target for the neurodevelopmental risk of the most widely used inhaled anesthetic in infants and young children.
GCSS Model Predicts TACE Plus Immunotherapy Response in Advanced HCC With 6-Marker Test
A multi-omics study has produced GCSS, a model that predicts how patients with advanced hepatocellular carcinoma will respond to TACE combined with immunotherapy. The model was streamlined into a multiplex immunohistochemistry assay requiring only 6 markers. Teams from Chongqing University Shapingba Hospital and Zhejiang University School of Medicine published the work in Cell Reports Medicine, titled "Multi-omics-driven personalized management of advanced HCC."
Scalable methylome-transcriptome profiling resolves clonal organization in human hematopoiesis
Droplet-MT jointly profiles transcriptomes and methylomes at ~10,000 cells per library, using methylation epimutations for mutation-independent clonal reconstruction and label transfer at ~0.2% CpG coverage to cut sequencing cost. Applied to ~21,000 paired profiles from healthy blood and longitudinal acute myeloid leukemia, it resolved small and expanded clones with heterogeneous lineage output and distinguished malignant clonal abundance changes, state remodeling within persistent clones, and recovery of healthy polyclonal hematopoiesis. Malignant monocytes stayed transcriptionally and epigenetically distinct from healthy and recovery-associated cells despite treatment-associated remodeling.
Disrupted chromatin architecture blocks B lymphopoiesis in Down syndrome
Three-dimensional genome architecture organizes human fetal haematopoiesis and explains the B-lineage defect in Down syndrome. Using ChromE-seq, a new single-cell assay jointly profiling chromatin conformation and transcription, the authors built a multimodal atlas of ~400,000 haematopoietic cells from disomic and trisomy 21 fetal liver. Trisomy 21 disproportionately disrupted B-lineage architecture, weakened an EBF1-centred regulatory circuit, and deleting a T21-sensitive EBF1 loop anchor reproduced the CLP-to-B-progenitor bottleneck seen in T21.
An iPSC-based experimental framework for investigating phenotypic variation associated with Jomon ancestry in the present-day Japanese population
Jomon ancestry, measured by the Jomon allele score, tracked with renal-related traits and serum triglycerides in 34,152 Tohoku Medical Megabank participants, and donors at JOM extremes (n = 10) showed group-level differences in immune-related gene expression. But when hiPSCs from those donors were differentiated into hepatocyte-like cells, intracellular triglycerides and lipid-related gene expression did not differ between groups. The work establishes a genetically characterized hiPSC framework for testing ancestry-associated phenotypes at the cellular level.
Ayahuasca plant genomes reveal retrotransposon-derived centromeres and contrasting routes to DMT and β-carbolines
Genome assemblies of the two ayahuasca source plants reveal contrasting histories: Psychotria viridis is an autopolyploid hexaploid (2n = 6x = 66) while Banisteriopsis caapi is diploid (2n = 2x = 20), yet centromeres of both are enriched in CRM-type Ty3/Gypsy retrotransposons. In P. viridis a single multifunctional methyltransferase catalyzes both N-methylations of tryptamine to DMT, whereas B. caapi makes beta-carbolines via dedicated enzymes plus a non-enzymatic, acetaldehyde-dependent Pictet-Spengler cyclization followed by enantioselective oxidation to harmaline. The work supplies the genetic structure of traditionally recognized cultivated varieties and the enzymes behind the alkaloids combined in the decoction.
Nature Paper Maps Spatial Proteome of Human Body and Cancers Across 2856 Clinical Samples
A Nature paper maps spatial proteome distribution across the human body and cancers, built from 2856 clinical specimens analyzed by DIA-MS and covering more than 13,000 proteins. The dataset spans 58 major tissue types, 251 tissue subtypes and 25 cancers, and traces proteome trajectories across physiological states including fetal, tumor, adjacent non-tumor and healthy adult tissue.
Contagion-preserving compression for multiscale epidemic modeling.
Iterative structural coarse-graining (ISCG) compresses large networks into multiscale representations that preserve contagion dynamics. In the saturation regime the compressed networks reproduce outbreak sizes, node-level infection risks, and spatiotemporal infection trajectories. Interventions designed on these representations, including influence maximization, immunization, and surveillance, consistently outperform adaptive centrality-based methods.
PreGame Algorithm Identifies Broad-Spectrum Anti-Tumor Gamma-Delta T Cells in Multiple Myeloma
A machine learning algorithm named PreGame, published in Nature, identifies broad-spectrum anti-tumor gamma-delta T cells in multiple myeloma. The work addresses a long-standing question of whether tumor-infiltrating gamma-delta T cells recognize myeloma cells directly through their TCR or via receptors such as NKG2D and NKp30 binding ligands on cancer cells. PreGame offers a computational route to select these cells, which combine innate-like and adaptive-like properties, for potential cell therapy.
Structural variants from donor-specific assemblies affect recurrent chromatin contact divergence in humans
Donor-specific genome assemblies markedly improve mapping of haplotype-resolved chromatin contacts: across 354 human and 12 nonhuman ape haplotypes, 13.2% of cis Hi-C contacts showed >25 kbp changes in inferred genomic separation and 2.8% more valid contact pairs were recovered compared with standard references. Haplotype-specific chromatin differences are selective, concentrating in 1,790 recurrent contact difference hotspots linked to 2,495 chromatin-structure-associated structural variants enriched in regulatory contexts and associated with expression variation; over 90% of these SVs arose in the human lineage. The work argues for building pangenome haplotype diversity into studies of 3D genome organization.
Methods and resources
HealthFlux world model keeps 20-year health predictions accurate and simulates drug effects across 1,256 diseases
HealthFlux, a pan-modal human health world model posted on medRxiv by Stanford postdoc Ying Kejun and colleagues, maintains a continuous 384-value health state trained on UK Biobank data spanning 11 data types including records, blood tests, plasma proteomics, metabolomics and MRI. In about 60,000 held-out participants it predicted 1,010 diseases and death over 5 years with an average AUROC of 0.832 versus 0.805 for RisQ, and after 20 years of autonomous rollout without new data it held 0.837 while Delphi-2M fell to 0.576. Simulated drug effects for 210 drug-disease combinations matched published clinical trials within 18%, and screening 259 drugs across 1,256 diseases suggested metformin cut 10-year mortality risk by about 21% and simvastatin cut major disease risk by about 35%.
A unified framework for quantitative splicing and transcript prediction
SpliceAI2 is a deep learning model trained end-to-end on splice site, splice junction, and transcript usage data across multiple mammalian species, and it reconstructs complete transcripts directly from genomic sequence. It improves detection and quantification of splice-altering variants across benchmarks covering cryptic splicing, splicing QTLs, and massively parallel reporter assays. In a rare disease cohort, predicted splice-altering variants account for 15% of the excess genetic burden, with about half in deep intronic regions likely missed by exome sequencing.
BoNTax: a curated genome-based framework for taxonomic classification and characterization of Clostridium botulinum Group I and Clostridium sporogenes
BoNTax decouples ANI-based species assignment from botulinum neurotoxin characterization for Clostridium botulinum Group I and Clostridium sporogenes. Analysis of 966 genomes informed selection of 46 references that resolved into two species clusters with within-species ANI >95% and between-species ANI <95%, supporting a 95% species threshold. Of 42 validation genomes, 29 of 32 reported assignments were concordant, three prompted re-evaluation, and ten unknown genomes received ANI-based assignments. BoNT typing, including bivalent strains, was fully concordant.
Opinion and commentary
medicalxpress.comPhysical activity weakens link between genetic risk and depression severity, long-term data suggest
Researchers at the University of Texas at San Antonio analyzed data from 23,517 adults in the NIH All of Us Research Program, combining depression polygenic risk scores, electronic health records and long-term Fitbit measurements averaging about 1.6 years per participant. Published in Nature Mental Health, the study found greater physical activity was associated with lower depression severity, with a stronger association among those with higher genetic vulnerability. The team aims to use such findings to develop personalized exercise recommendations for depression prevention and management.
[Health Policy] Strengthening health systems to prioritise, provide care, and prevent osteoarthritis: a roadmap for global health policy
The Lancet outlines a roadmap for global health policy on osteoarthritis, projecting that by 2050 almost 1 billion people will live with the condition, which currently has no cure. It argues that osteoarthritis remains largely invisible in national and global health agendas and poorly integrated into chronic care service models. The roadmap calls for strengthening health systems to prioritise, provide care for, and prevent the disease.
Migraine.
Migraine is a chronic neurovascular disorder marked by recurrent moderate-to-severe head pain with disabling symptoms including aura, nausea, vomiting, phonophobia and photophobia. Its pathogenesis involves genetic and epigenetic factors across complex neurosensory and neurovascular networks. Decades of research have driven mechanism-based therapies that are transforming clinical practice and improving patients' lives.
In brief
- Spatiotemporal AI modeling of gene regulation and variant effects in the developing human brainbiorxiv.org
- Gene-environment interaction loci with signatures of mid- to late Holocene selection show evidence for diet-dependent genetic effectsbiorxiv.org
- New genetic candidates help explain why autism affects males more often than femalesmedicalxpress.com
- Cellular and molecular census of the pleiotropic disease locus Negr1 in zebrafishbiorxiv.org
Also today
4 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
ClinicalTelitacicept Approved in China as argenx Stops Efgartigimod UNITY Phase III in Sjögren's Syndrome1 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- Telitacicept Approved in China as argenx Stops Efgartigimod UNITY Phase III in Sjögren's SyndromeUpdateCompetition among Sjögren's syndrome drugs has shifted to patient stratification, long-term treatment and market access. Telitacicept has been approved in China, where RemeGen has entered commercialization, while Novartis and Amgen have each reported positive Phase III results. On October 8, 2026, argenx terminated the UNITY Phase III study of subcutaneous efgartigimod in the same indication.
OtherNMPA Approves Datopotamab Deruxtecan for Metastatic Triple · FDA Approves Teva's WELTRUZA Long · TRexBio3 ▾▴
Everything else with a concrete event that did not make the daily.
- NMPA Approves Datopotamab Deruxtecan for Metastatic TripleUpdateChina's NMPA has approved a new indication for Daiichi Sankyo (China)'s datopotamab deruxtecan injection, for adults with unresectable or metastatic triple-negative breast cancer who are not suitable for PD-1/PD-L1 inhibitor therapy. The approval, shown on the NMPA website on October 8, 2026, was detailed in a Daiichi Sankyo press release. Triple-negative breast cancer accounts for about 10%-15% of all breast cancers and is aggressive with high recurrence and poor prognosis.NMPA
- FDA Approves Teva's WELTRUZA LongUpdateThe US FDA has approved Teva's WELTRUZA (olanzapine) extended-release injectable suspension for the treatment of schizophrenia in adults, Teva announced on October 9, 2026. Delivered as a long-acting injection, it is intended to reduce the adherence problems associated with daily oral olanzapine dosing. It now becomes an additional long-acting option for adult patients with the condition.FDA
- TRexBioUpdateTRexBio, a clinical-stage biotechnology company developing fusion proteins and antibody immunomodulatory drugs based on tissue regulatory T cell (Treg) biology, has completed its IPO. The offering comprised 8,333,334 common shares priced at $14.00 each, raising about $116.7 million (roughly RMB 781 million). Eli Lilly indicated interest in subscribing at the IPO price, which would keep its stake at no more than 19.9% of shares outstanding after the offering.